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ABSTRACT 
Predicting the future is a dangerous undertaking at best, and not meant for the faint-hearted. However, viewing the 
advances in molecular medicine, genomics and proteomics, it is easy to comprehend those who believe that molecular 
imaging methods will open up new vistas for medical imaging. The knock on effect will impact our capacity to diagnose 
and treat diseases. Anatomically detectable abnormalities, which have historically been the basis of the practice of 
radiology, will soon be replaced by molecular imaging methods that will reflect the under expression or over expression 
of certain genes which occur in almost every disease. Molecular imaging can then be resorted to so that early diagnosis 
and characterisation of disease can offer improved specificity. Given the growing importance of molecular medicine, 
imagers will find it profitable to educate themselves on molecular targeting, molecular therapeutics and the role of 
imaging in both areas. © 2006 Biomedical Imaging and Intervention Journal. All rights reserved. 
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While medicine has taken on a molecular character 
and the Human Genome Project has yielded a wealth of 
information for mapping the human body, nothing really 
explains how the body works. Molecular imaging will 
play a key role in delivering molecular medicine since it 
defines many cellular and biochemical mechanisms [1]. 
It must be said that although the term “molecular 
imaging” is relatively new, the underlying concept has 
been the basis of many nuclear medicine procedures for 
over half a century. In fact the imaging of biological 
processes is central to the scientific method in natural 
sciences [2]. The term molecular imaging can be broadly 
defined as the “visualisation and characterisation of 
biologic processes at the cellular and molecular level in 
vivo”. And this has been primarily catalysed by two 
concurrent developments, namely the understanding of 
the molecular basis of disease, and the development of 
drugs directed at these molecular targets.  
Molecular imaging is a growing research discipline 
(and increasingly a clinical discipline too) aimed at 
developing and testing novel tools, reagents, and 
methods to image specific molecular pathways with 
whole body imaging instruments in vivo. The pathways 
targeted play a key role in disease processes. Molecular 
imaging holds the unique potential of being able to find, 
diagnose and treat disease in vivo simultaneously (i.e., 
inside the body), as well as depict how well a particular 
treatment is working i.e., theragnostics. This is in 
contrast to "classical" diagnostic imaging where most of 
 
Present address: Department of Biomedical Imaging (Radiology),
Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur,
Malaysia. Tel.: +603-79492069; Fax.: +603-79581973; E-mail: 
basrij@ummc.edu.my (Basri J.J. Abdullah). BJJ Abdullah. Biomed Imaging Interv J 2006; 2(4):e28   2 
    This page number is not 
    for citation purpose 
 
diseases are diagnosed based on the manifestation of 
signs and symptoms following which remedial therapy is 
then applied to modify or ameliorate those symptoms. In 
most diseases, since the origins are often unknown and 
even in those instances where it is known, the treatments 
are meant at best to keep things under control.  
Molecular imaging exploits specific molecules as 
the source of image contrast. This paradigm shift from 
non-specific physical to specific molecular sources 
underlies many of the current molecular imaging 
research efforts. It is this search for the “holy grail” of 
modern medicine that may make it possible eventually to 
manipulate an individual's genetic constitution 
appropriately, to get rid of disease processes.  
Molecular imaging is to a certain extent technology 
driven since molecular information can be obtained with 
some “high-end” imaging technologies. To do more 
would require newer equipment. However, on a 
conceptual level, molecular imaging is neither about 
technology nor about a change in the practice but 
essentially another revolution in the way medicine is 
viewed. One underlying premise of molecular imaging is 
that this emerging field is not defined by the imaging 
technologies that underpin acquisition of the final image 
per se but rather by the underlying biological questions 
of medicine. The ramifications will be felt in every nook 
and cranny of medical practice and then extend into the 
legal, social and ethical aspects of society. No concept 
and basis of medicine, currently practiced will be spared.  
As a consequence, a new approach to wellness, 
disease prevention and treatment needs to be developed 
to counter the effects of poor health and illness, 
especially in the world’s less developed countries. To 
enhance such an approach, the potential contributions of 
biomedical imaging, bioengineering, and bioinformatics 
to emerging research areas, such as functional genomics, 
proteomics, molecular biomechanics and drug delivery 
systems, tissue and cell engineering, quantitative biology 
and computer modelling, molecular and computational 
imaging, computer-aided diagnosis, metabolic imaging, 
ultra fast and integrated imaging systems are of prime 
importance. In the current phase of the increasingly 
complex and ever changing health care environment, 
governments, medical speciality organisations, 
researchers, vendors, and providers are finding it hard to 
cope with these challenges alone. Partnerships are 
critical to face any new concept. It is therefore 
imperative that new relationships sharing the risk of 
adopting new technological innovation, programmes, 
services and processes designed to improve overall 
patient care be worked at.  
Increasingly, the power of molecular imaging comes 
from the capacity to harvest vast amounts of knowledge 
gained from molecular biology. Currently we can 
theoretically design a molecular imaging agent to target 
each step in the sequence from DNA replication to 
protein synthesis and subsequently all the steps of 
protein metabolism. To begin investigating molecular 
signals in vivo, researchers have already developed and 
characterised methods for imaging endogenous proteins, 
such as receptors, transporters, or enzymes and their 
respective functions. More recently, methods have also 
been validated to analyse specific expression of 
transgenes of interest. This is typically performed by 
quantifying the activity of reporter genes delivered by a 
viral vector, as used in gene therapy, or through use of 
exogenous reporter genes in genetically engineered cells 
[3] and transgenic mouse models [4]. 
Processes in the human body are extremely complex 
and depend on a multitude of factors. As such, they are 
much more difficult to analyse than a laboratory sample. 
In fact, metabolic processes can only be truly understood 
in vivo. If we could improve the analysis of metabolic 
reactions in living organisms, it would lead to immense 
savings for the pharmaceutical companies and open a 
promising market. Methods that produce visual images 
are being used with increasing frequency to study 
metabolic processes, e.g., to find out when individual 
genes become active (are expressed). Here, highly 
specific molecules (probes) are employed, which often 
are customised with genetic engineering. These special 
molecules search for a specific substance and, when they 
have found it, link with it and emit signals that can be 
depicted visually to provide a diagnosis of changes to a 
patient's metabolism. The key elements to sampling 
molecular information are [5]: 
●  The use of special imaging probes with high 
specificity. In fact due to the advances in 
chemistry and screening it is possible to have 
increased specificity without sacrificing 
sensitivity.  
●  The availability of appropriate amplification 
strategies 
●  High resolution images from systems with 
increased sensitivity, and 
●  Capability of overcoming biological barriers to 
delivery of probes  
 
With regard to the strategy for imaging these probes: 
●  Direct imaging uses a probe specific for cell 
surface receptors, intracellular molecules or 
gene expression, which interacts directly with 
the target providing an image intensity 
correlating to the amount of target actively 
present. 
●  Indirect imaging is more complicated as it often 
uses both a reporter gene and a reporter probe 
which interacts within specifically targeted 
cells to produce a metabolite trapped in the 
cells that is visualised when scanned. 
●  Surrogate imaging detects downstream effects 
of endogenous molecular-genetic processes 
using established radiopharmaceuticals and 
clinical imaging protocols. 
 
Regarding the imaging probes there are three basic 
types [6]: 
●  The compartmental probe typically assesses 
physiological parameters (i.e., flow and 
perfusion) and as mentioned above the probe BJJ Abdullah. Biomed Imaging Interv J 2006; 2(4):e28   3 
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does not directly image the molecular process 
but a surrogate. 
●  Targeted probes act directly against a specific 
moiety targeted to the molecule, receptor or 
enzyme of interest or an imaging component 
that provides the physical contrast.  
●  Finally, “smart” probes activate exclusively in 
the presence of their intended target and since 
there is no significant background signal, smart 
probes have a significant signal advantage over 
simple targeted agents. Primarily because 
probes need to be biocompatible, the presence 
of additional delivery barriers [7], and the 
necessity for developing special in vivo 
amplification strategies [8], in vivo molecular 
imaging is more challenging than in vitro 
detection.  
 
Optical imaging technology (including diffuse 
optical tomography, phase-array detection, photon 
counting, near-infrared fluorescence imaging), high-
spatial-resolution MR and nuclear imaging techniques 
(e.g., positron emission tomography [PET]), fusion 
imaging and micro imaging systems (micro CT, micro 
MR, micro US) play an important role in the field. Each 
of these techniques has its particular advantages and 
disadvantages, and the use of one or the other technique 
is mostly dependent on the specific research question and 
hypothesis to be tested [2].  
Radionuclide imaging devices visualise very low 
concentrations of radionuclide probes (nano- to 
femtomolar) in real-time [8] and provide quantitative 
information [9], but with low image resolution. They can 
be used for whole body imaging. PET is frequently used 
when a substrate to a given target exists that can easily 
be labelled with a positron emitter, for example labelled 
2'-fluoro-5-iodovinyl-1-ß-D-arabinofuranosyl-uracil 
(FIAU) or ganciclovir for imaging of viral thymidine 
kinase gene expression. Radio nucleotide imaging 
combined with a computed tomography (CT) or a 
magnetic resonance imaging (MRI) scan provides high 
anatomic definition along with functional imaging for 
precise location of the selected molecular activity. 
Nuclear imaging techniques are suited to track small 
amounts of labelled therapeutic drugs, and to investigate 
multiple drug resistance, or delivery systems such as 
viral vectors. However the downside is the need for a 
cyclotron and high cost.  
Magnetic Resonance Imaging’s (MRI) ability was 
enhanced significantly with the development of 
functional MRI. The revival of interest in molecular 
imaging has expanded the frontiers of MRI even further. 
MR imaging has two particular advantages over 
techniques that involved the use of isotopes, namely the 
higher spatial resolution (micrometer rather than several 
millimetres), and the simultaneous extraction of 
physiologic and anatomic information.  
In comparison with isotope techniques, however, 
MR imaging is several magnitudes less sensitive 
(millimolar rather than picomolar), which is why reliable 
signal amplification strategies must be developed. MR 
techniques in cell imaging are also maturing where cells 
are induced to take-up superparamagnetic iron oxide 
formulations [10].  
Ultrasound in molecular imaging allows real-time 
imaging with resolution of less than 50 µm. With the 
developments of microbubble technology [11] and 
harmonic imaging, ultrasound is increasingly being used 
to translate molecular processes in vivo. Even though CT 
is often not recognised as a modality for molecular 
imaging, it has a role especially for the study of soft 
tissue tumours in bone and lung because of its low cost, 
reasonable resolution and fast scanning times.  
Finally, optical imaging techniques have already 
been developed for applications in molecular and cellular 
biology (e.g., fluorescence microscopy) and in vivo 
surface imaging [12]. One of the appealing advantages of 
near-infrared optical imaging is that quenched 
fluorescent labels that become brightly fluorescent after 
specific molecular interactions with their targets, can be 
used.  
Another notable advantage of optical techniques is 
multiple probes with different spectral characteristics can 
be used for multichannel imaging, similar to in vitro 
karyotyping [3]. In addition, it is reasonably cheap, has 
good spatial resolution and possesses nanomolar 
sensitivity. Newer approaches have been advocated that 
may ultimately lead to the development of tomographic 
optical imaging systems in the near-infrared spectrum. 
These have been suggested to overcome depth 
penetration.  
Today's scientists are not just looking at specific 
molecules, but are also evaluating the components within 
the nucleus of their cells. They are learning what causes 
the cells to turn on and off, what makes them do what 
they do and how their fundamental function can be 
boosted or shut down. While molecular imaging has 
significantly advanced oncology, cardiology, neurology, 
infectious disease detection and therapy, drug 
development, and disease treatment, even more is 
expected. Here is what molecular imaging promises:  
Detecting disease 
In the future, advances in molecular imaging will 
lead to the development of a broader array of imaging 
probes that will cover all the body's major systems and 
associated disease types, making even earlier detection 
of disease possible. Our capacity to image these 
molecular changes will directly affect patient care by 
allowing much earlier detection of diseases, e.g. image 
molecular changes that we currently define as 
"predisease states". If such a situation came to pass, then 
we would allow intervention when the outcome can be 
significantly altered. Because of the greater specificity of 
the imaging probes and techniques we would be able to 
look for specific cell types, e.g., cancer cells have an 
increase in metabolic activity in comparison with normal 
cells. This fact makes it possible to image cancer cells in 
vivo using deoxyglucose, a metabolic substance that is 
voraciously glycolised and trapped by targeted cancer BJJ Abdullah. Biomed Imaging Interv J 2006; 2(4):e28   4 
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cells. By labelling deoxyglucose with a radioactive agent 
and injecting the resulting molecular imaging agent into 
patients, scientists can make nuclear images of the 
primary tumour as well as metastatic sites throughout the 
body. 
When a cell is dying (apoptosis), it turns inside out, 
presenting an otherwise unexposed protein binding site. 
The body responds by producing a protein called annexin, 
which seeks out and connects to the binding site of these 
dying cells to “tag” them for destruction by the immune 
system. By creating a human annexin, attaching it to the 
imaging agent technetium and injecting it into the patient, 
scientists can “seek and illuminate” dying cells. 
Physicians can use this information to decide whether to 
change or keep a patient’s therapy regimen. For example, 
when chemotherapy or radiotherapy is used to kill cancer 
cells, apoptosis occurs. Apoptosis is the necessary death 
of cells to make way for new cells and to remove cells 
where DNA has been damaged to the point at which 
cancerous change is likely to occur. If the chosen therapy 
is effective, apoptosis can be demonstrated within 24 to 
48 hours. Physicians can use molecular imaging to 
determine whether apoptosis has occurred and can 
change the therapy if it does not. Not only does this 
ability mean that the treatments used will be more 
effective, but further costs associated with ineffective 
therapy can be avoided. This can be done using SPECT 
(single photon emission computed tomography) or MRI. 
In the example quoted above if therapy is proving 
effective, then, annexin could be used as a delivery 
vehicle to further enhance cell death. Physicians would 
add a payload of radioactive toxin to annexin. When 
injected, the “loaded” annexin will deliver the toxic 
agent to the site of the dying cancer cells to cause even 
more cells to die. This process creates a cycle of cell 
death because the more cells that die, the more toxin-
loaded annexin will be attracted to the cancer site. This 
molecular chain of events helps accelerate the therapy’s 
effectiveness. 
With the US Food and Drug Administration's (FDA) 
approval of
 Avastin (Bevacizumab; Genentech, Inc., San 
Francisco, CA) as
 a first-line treatment for patients with 
metastatic colorectal
 cancer, it was a major landmark in 
the field of angiogenesis. With the development of an 
image based angiogenetic marker, it would help select 
patients for
 appropriate therapeutic regimens including 
the most appropriate
  combination of angiogenic and 
other therapeutic agents, help
 to identify the optimal time 
window and the appropriate dosage
  of the different 
therapeutic agents, assist in monitoring the
  effects of 
such treatments, and provide functional information
 for 
adjusting the therapeutic regimens over time in an 
interactive
  basis [13]. Since imaging can potentially 
provide morphologic,
  functional and molecular 
information in a spatially and temporally
  resolved 
manner, many investigators have incorporated imaging
 
into pre-clinical studies and clinical trials of angiogenesis
 
therapies. 
Further developments are occurring where imaging 
and therapeutic agents are tagged with a targeted 
molecular agent are being developed and this may 
enhance treatment e.g. Zevalin (Ibritumomab tiuxetan, 
IDEC Pharmaceuticals, Cambridge, MA), a therapeutic 
regimen for treatment of relapsed or refractory low grade, 
follicular or transformed B-cell non-Hodgkin's 
lymphoma. Indium-111 labelled Zevalin scanning allows 
visualisation of disease and calculation of dose to be 
delivered by Yittrium-90 labelled anti-CD 20 
monoclonal antibodies [14].  
Current evidence suggests that one course of anti-
CD20 radio immunotherapy is as efficacious as six to 
eight cycles of combination chemotherapy. 
Decreased tissue oxygen tension is a component of 
many diseases. Although hypoxia can be secondary to a 
low inspired P02 or a variety of lung disorders, the 
commonest cause is ischemia due to an oxygen demand 
greater than the local oxygen supply. In tumours, low 
tissue p02 is often observed, most often due to a blood 
supply inadequate to meet the tumour's demands. 
Decreased tissue oxygen tension is a component of many 
diseases. In the heart tissue hypoxia is often observed in 
persistent low-flow states, such as hibernating 
myocardium. In patients with stroke, hypoxia has been 
associated with the penumbral region, where an 
intervention could preserve function. In some tumours 
the efficacy of conventional radiotherapy is limited by 
the
  presence of a hypoxic, radioresistant, and repair-
proficient
 subset of tumour cells.  
Despite the potential importance of oxygen levels in 
tissue, difficulty in making this measurement in vivo has 
limited its role in clinical decision making. This has led 
to the development and testing
  of hypoxic imaging 
techniques and agents. An ideal hypoxia imaging agent 
should have high membrane permeability for
 easy access 
to intracellular mitochondria and low redox potential to 
confer
 stability in normal tissue, but it should be able to 
be reduced by
  mitochondria with abnormally high 
electron concentrations in hypoxic cells. Imaging with 
some of these agents can provide direct evidence of 
tissue with low oxygen levels that is viable. In the 
experimental setting this information is useful to plan a 
more aggressive approach to treating tumours, or 
revascularise a heart suffering ischemic dysfunction. 
Oxygen electrode measurements in animal experiments 
have demonstrated a strong correlation between low 
tumour pO2 and excess 
60Cu-diacetyl-bis(N(4)-
methylthiosemicarbazone (
60Cu-ATSM) accumulation. 
Some studies have suggested that pretreatment imaging 
with 
18F-2-fluoro-2-deoxy-D-glucose(FDG)
  and 
64Cu-
ATSM would allow stratification of tumour phenotypes
 
such that those tumours that are most susceptible would 
be selected
 for treatment [15]. 
Aiding and assessing response to therapy 
Currently treatment instituted for most diseases is 
based on “one size fits all”. This is based on our inability 
to separate the responders from those who are either not 
likely to respond or those that may actually develop more 
complications from the treatment offered. But 
increasingly many new-generation therapeutic drugs are BJJ Abdullah. Biomed Imaging Interv J 2006; 2(4):e28   5 
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designed with highly specific molecular targeting 
capabilities and delivery mechanisms. By directly 
imaging the underlying alterations of diseases, we have 
the potential to be able to directly image the effects of 
therapy. This would provide an opportunity to play a 
direct role in determining the efficacy of treatment. 
Further, response to therapy could be assessed shortly 
after therapy has been initiated and not in the many 
months subsequently as required today to determine 
whether pharmacological or biological intervention has 
been beneficial.  
In addition the toxic effects of treatment on the 
patient's healthy tissue can be avoided. In the future, 
molecular imaging is expected to aid in identifying the 
presence of drug-resistant genes that will enable 
clinicians to pre-determine which treatment regimens 
will be most effective within an hour of initiating 
treatment and avoid delays in optimizing a patient's 
therapy.  
Furthermore, molecular tracers, or 
radiopharmaceuticals, will be used to create diagnostic 
images which visually indicate whether cancer patients 
are susceptible to multi-drug resistance, a condition in 
which the defensive response to one type of 
chemotherapy also diminishes the potency of other 
chemo agents. With this information, physicians can 
make accurate and fairly rapid diagnoses and provide 
patients with more precise treatment. 
Others are working on
  nanoparticle delivery 
platforms that can potentially deliver
 both imaging and 
therapeutic agents to endothelial targets.
 Using a vascular 
targeted imaging agent for selecting patients
 to be treated 
and for monitoring response with the therapeutic
 agents 
delivered via the same delivery vehicle satisfies the
 
requirements for "personalised treatment" [16-18]. 
Enabling nano-treatments  
It may seem like the movie, Osmosis Jones (Warner 
Bros) where researchers are working to integrate 
molecular imaging with nanotechnologies (human-made, 
molecular-size structures or machines) to detect disease 
and enable even more precise therapy in many instances 
eliminating if not minimising the need for surgery 
entirely. Some of envisioned scenarios may include the 
development of biosensors providing the exact location 
of disease, and new nanotechnologies which can be 
dispatched into the body that can deliver drug therapies 
directly to cancerous cells by affixing themselves to 
those specific cells and releasing cancer-killing agents.  
Just like nano-robots, these nanotechnologies shall 
be designed to self-assemble themselves at the 
appropriate place and time following which they are able 
to repair bones or tears and if necessary stimulate the 
growth of new blood vessels or tissue. There would 
additionally be imaging technologies which could 
monitor the process, ensure that it is working properly, 
and measure the results, the ultimate of image guided 
minimally invasive surgery! 
Drug discovery cycle 
Molecular imaging will facilitate the development of 
new drugs, by providing early stage chemical 
compounds that will enable researchers in the public and 
private sectors to validate new drug targets, which could 
then move into the drug-development pipeline. This is 
particularly true for rare diseases, which may not be 
attractive for development by the private sector. Three 
key technological advances drive NIH’s effort to build 
small molecule libraries.  
●  The successful completion of the Human 
Genome Project has provided an enormous 
cache of human biology to be studied and 
potential drug targets to be discovered.  
●  Developments in chemistry have given 
researchers in the public sector the ability to 
synthesise large numbers of related molecules, 
a capability previously available only to 
researchers in pharmaceutical and 
biotechnology companies.  
●  Advances in robotic technology and informatics 
now allow scientists to screen hundreds of 
thousands of compounds in a single day, an 
orders of magnitude greater capacity than was 
available a decade ago [19].  
 
Molecular imaging is a powerful concept that 
envisions the promise of disease characterisation / 
phenotyping and early assessment of therapeutic efficacy. 
From this, it is a logical step to envisaging “personalised 
medicine,” where disease phenotyping will be used to 
tailor the most optimum therapeutic regimen patient by 
patient and not the usual one size fits all. This is already 
happening but is not directly related. Imaging entails the 
use of Her-2/neu gene expression as an indicator of 
whether breast cancer patients will respond to the drug 
Herceptin, a monoclonal antibody.  
Today the power of imaging is so sophisticated that 
we now have the capacity to identify unresolved 
biological and clinical questions and focus on how 
imaging techniques might be used to solve these 
problems. Emphasis continues to be on minimising 
invasiveness, reducing image processing time, lower cost, 
less radiation dose but at the same time maximising 
resolution and contrast as well as easy interpretation of 
data. Future advancements lie in not only in new 
modalities e.g. optical imaging but also in improved 
imaging modalities as well in producing displays that 
intelligently combine structural, chemical, electrical, 
magnetic, acoustic, and motion information.  
However though in the past, diagnostic imaging 
tests were
 designed to be stand alone investigations with 
specialised image
 acquisition, analysis and display, it is 
important that we do
 not continue to utilise diagnostic 
imaging tests in this same manner, but rather
 exploit the 
synergies between each individual i.e. the sum of the 
parts is larger than each alone! For example, the 
development of PET/CT systems allows the synthesis of 
the rich metabolic and
  functional information gained 
from PET with the morphologic information provided by BJJ Abdullah. Biomed Imaging Interv J 2006; 2(4):e28   6 
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CT, new information
  can be gained that cannot be 
obtained with each modality alone.
 These multi-modality 
systems (together or image fusion from two separate 
systems) is only the beginning of what may prove to be a 
significant
  paradigm shift in medical imaging device 
design and manufacturing [20].  
Molecular imaging promises to become a powerful 
addition to the ammunition of medical imaging. “Who 
controls and gives direction to that growth remains 
arguably an open question. Today’s imaging research 
defines the practice of the future” [2]. Leaders in 
imaging generally will be well served to acquire the 
knowledge necessary to incorporate these new methods 
into their practices, including knowledge of fundamental 
principles in molecular biology. They should also 
promote education and research that will undoubtedly 
impact the future of imaging.  
The 21st century will witness further innovation, 
growth and clinical utility imaging and therapy. These 
challenges are already formidable enough for imaging 
community in the developed world but be daunting for 
those in the developing countries where meeting the 
current imaging needs is at most times, barely sufficient. 
Despite these challenges, we in the Southeast Asian 
region must make a concerted and co-ordinated effort to 
ensure that we are not left behind. The following are 
some of the actions that will help ensure that the imaging 
community here does not lag behind. 
Firstly, leaders in imaging generally should 
recognise the importance of this new and rapidly 
expanding field. They need to encourage acquisition of 
knowledge necessary to incorporate these new methods 
into their practices, including knowledge of fundamental 
principles in molecular biology. They should also 
promote education and research that will undoubtedly 
impact the future of imaging. 
Although we may not be able to change the current 
line of thinking of the current practitioners; the future 
generations however, must be aware of the developments 
in molecular imaging and so there must be changes in the 
curriculum with introduction of subjects like 
biochemistry, immunology, as well as oncology. This is 
being incorporated in the new integrated curriculum 
implemented in some institutions.  
Thirdly, there should be greater co-operation as well 
as coordination between the regional societies, e.g., 
ASEAN Association of Radiology and Asian-Oceania 
Society of Radiology, in promoting greater awareness of 
biomolecular imaging. This is being done by the 
introduction of specific seminars and conferences [21], 
and would certainly go a long way in ensuring greater 
awareness and interest. Greater co-operation with other 
regional societies, e.g., the European Congress of 
Radiology (ECR), will also facilitate this process with 
the availability of online teaching materials [22] from the 
conferences. 
Finally, the setting up of local, national or regional 
centres of excellence in biomolecular imaging would be 
another initiative to ensure and maintain the lead. These 
centres are also important since the disease patterns and 
demographics are very different from that in the West. 
However, setting up such centres is intensive: both 
financially and in terms of human resource and is 
probably beyond the reach of many countries but 
Singapore [23], Thailand and Malaysia would surely be 
able to do so if they have not already done so. Such 
centres should be involved in the training of the new 
generation of imaging specialists and should provide for 
cross training and fellowships.  
This potential requires interdisciplinary partnerships 
and collaborative efforts between physicians, medical 
physicists, biomedical engineers and computer scientists. 
We will all need to learn each others’ technical language 
to move forward. The setting up of a regional journal 
such as biij (www.biij.org) is also essential in putting all 
these different aspects together. It also provides a forum 
for publication, dissemination, and discussion as well as 
networking between the different groups and 
organisations in the region. 
In view of these changes, as well as the increasing 
emphasis on imaging at the cellular level or even at the 
genetic level, research in the field of biomedical imaging 
is set to explode. 
Impossible is nothing! 
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